Lupus Nephritis Drug Approvals and Access Advances

NICE greenlights LN treatment; Roche's Gazyva gets positive reimbursement backing in Canada. Aurinia launches PRESERVE Phase 4 trial combining LUPKYNIS with belimumab, obinutuzumab, or anifrolumab. Real-world belimumab spacing study (22 patients, no flares over 21 months) supports personalized tapering. IVIG achieved remission in refractory class V LN after standard therapy failure. STAR cohort challenges routine RASi use during active LN induction. A new single-center LN study from Jordan reports only 46% complete remission, with low C3 at diagnosis strongly predicting non-response, reinforcing early aggressive treatment. A post hoc analysis of belimumab trials shows remission rates double when steroid caps are removed, with racial disparities. A deep profiling study of lupus nephritis kidneys reveals dynamic immune responses, adding mechanistic insights into LN pathogenesis. New real-world data on glucocorticoid tapering during belimumab treatment shows steroid reduction benefits. A recent cost-effectiveness study shows starting belimumab within 2 years of diagnosis yields better QALYs and saves $126K per patient vs. delaying, supporting earlier biologic use to prevent irreversible organ damage. Emerging adjunct: Dapagliflozin (SGLT2 inhibitor) shows potential renal and hematologic benefits in LN, adding a novel treatment angle. Post hoc BLISS-LN confirms belimumab+MMF improves renal outcomes in proliferative LN (CRR 32.6% vs 17.6%). KDOQI commentary on KDIGO LN guideline offers fresh perspective on US implementation, reinforcing earlier detection, combination therapy, steroid minimization, and newer agents like obinutuzumab and CAR-T.